CCA
BMY icon

Cravens & Co Advisors’s Bristol-Myers Squibb BMY Stock Holding History

Cravens & Co Advisors’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$340K Buy
5,611
+120
+2% +$7K 0.22% 54
2025
Q4 		$307K Sell
5,491
-23
-0.4% -$1.11K 0.2% 51
2025
Q3 		$249K Buy
5,514
+122
+2% +$5.7K 0.17% 53
2025
Q2 		$250K Buy
5,392
+88
+2% +$4.32K 0.19% 50
2025
Q1 		$323K Buy
5,304
+18
+0.3% +$1.05K 0.25% 45
2024
Q4 		$299K Buy
5,286
+8
+0.2% +$447 0.23% 52
2024
Q3 		$273K Sell
5,278
-565
-10% -$26.5K 0.21% 55
2024
Q2 		$243K Buy
+5,843
New +$261K 0.18% 64

Other funds holding BMY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Cravens & Co Advisors's BMY Position: Q1 2026 in Review

Cravens & Co Advisors increased its Bristol-Myers Squibb (BMY) stake by 2.2% in Q1 2026, buying an estimated $7K and bringing the position to 5,611 shares worth $340K. The position accounts for 0.22% of the portfolio, ranked #54.

Cravens & Co Advisors first reported a position in BMY in Q2 2024 and has held it in 8 quarters since. 2,518 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Cravens & Co Advisors held 5,611 shares of Bristol-Myers Squibb worth $340K as of Q1 2026.
  • Cravens & Co Advisors bought 120 Bristol-Myers Squibb shares in Q1 2026, an estimated $7K.
  • Bristol-Myers Squibb made up 0.22% of Cravens & Co Advisors's portfolio in Q1 2026, its #54 holding.
  • Cravens & Co Advisors first reported a position in Bristol-Myers Squibb in Q2 2024 and has held it in 8 quarters since.
  • 2,518 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Cravens & Co Advisors's 13F filing for Q1 2026, filed 14 May 2026.